Ripretinib 150 mg
150 mg · ITT
GIST after imatinib, sunitinib and regorafenib
Comparator: placebo
median progression-free survival (BICR): 6.3 months, primary analysis
progression-free survival hazard ratio vs placebo: 0.15 HR, primary analysis
objective response rate (BICR): 9%, primary analysis
median overall survival: 15.1 months, not tested for significance
INVICTUS · NCT03353753
Placebo
placebo · ITT
GIST after imatinib, sunitinib and regorafenib
median progression-free survival (BICR): 1 months, primary analysis
median overall survival: 6.6 months, 66% switched to ripretinib
INVICTUS · NCT03353753
Ripretinib 150 mg
150 mg · ITT
GIST after imatinib (ITT n = 226)
Comparator: sunitinib 50 mg 4/2
median progression-free survival (IRR), ITT: 8 months, primary analysis
progression-free survival hazard ratio vs sunitinib, ITT: 1.05 HR, primary analysis; not significant
median progression-free survival, KIT exon 11 ITT: 8.3 months, primary analysis
objective response rate, KIT exon 11 ITT: 23.9%, primary analysis; nominal P = .03
median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 14.2 months, exploratory, Exploratory ctDNA analysis (Heinrich, Nat Med 2024); nominal P
INTRIGUE · NCT03673501
Sunitinib 50 mg 4/2
50 mg · ITT
GIST after imatinib (ITT n = 227)
median progression-free survival (IRR), ITT: 8.3 months, primary analysis
median progression-free survival, KIT exon 11 ITT: 7 months, primary analysis
objective response rate, KIT exon 11 ITT: 14.6%, primary analysis
median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 1.5 months, exploratory
median PFS, exploratory ctDNA KIT exon 11 + 13/14 (sunitinib vs ripretinib 4.0): 15 months, exploratory
INTRIGUE · NCT03673501